This invention relates to dihydro-benzo[b][1,4]diazepin-2-one derivatives of the formula
1
wherein R
1
, R
2
, X and Y are as defined in the specification and R
3
is a six-membered aromatic heterocycle containing 1 to 3 nitrogen atoms or a pyridine-N-oxide as further defined in the specification. The invention further relates to medicaments containing these compounds, a process for their preparation as well as their use for preparation of medicaments for the treatment or prevention of acute and/or chronic neurological disorders.
The electrophilic behavior of the reactive entity in the phtosubstitution of benzenes with 2-iodopyridine was found to be ascribable to the intermediary 2-pyridyl cation, rather than to the electrophilic 2-pyridyl radical.
A Pd-catalyzed highly selective direct diarylation of pyridines has been developed using a transient activator strategy. Both (MeO)2SO2 and Cu2O are required for this transformation. The in situ generated N-methylpyridinium salt can be arylated at both 2- and 6-positions under the cooperative Pd/Cu catalysis. A subsequent N-demethylation then gives the 2,6-diarylpyridines. This protocol provides a
已使用瞬态活化剂策略开发了Pd催化的吡啶的高选择性直接二芳基化反应。两者(MEO)2 SO 2和Cu 2需要用于该转化O操作。原位生成的N-甲基吡啶盐可以在Pd / Cu协同催化下在2-位和6-位芳基化。然后,随后的N-去甲基化得到2,6-二芳基吡啶。该协议为对称的2,6-二芳基吡啶提供了一种新颖的合成途径。
[EN] COMBINATION OF MGLUR2 ANTAGONIST AND ACHE INHIBITOR FOR TREATMENT OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS<br/>[FR] COMBINAISON D'ANTAGONISTE MGLUR2 ET D'INHIBITEUR ACHE DESTINEE AU TRAITEMENT DE TROUBLES NEUROLOGIQUES AIGUS ET/OU CHRONIQUES
申请人:HOFFMANN LA ROCHE
公开号:WO2005014002A1
公开(公告)日:2005-02-17
The present invention relates to a method of treatment or prevention of acute and/or chronic neurological disorders, to a pharmaceutical composition comprising an inhibitor of acetylcholinesterase (AChE inhibitor) and a metabotropic Glutamate receptor 2 antagonist (mGluR2 antagonist), to the use of an AChE inhibitor and a mGluR2 antagonist in the preparation of a medicament, and. to kits comprising an AChE inhibitor and a mGluR2 antagonist.